Successful bortezomib-based treatment in POEMS syndrome

Eur J Haematol. 2009 Dec 1;83(6):609-10. doi: 10.1111/j.1600-0609.2009.01330.x. Epub 2009 Aug 6.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Depression, Chemical
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Drug Therapy, Combination
  • Humans
  • Male
  • Melphalan / administration & dosage
  • POEMS Syndrome / diagnosis
  • POEMS Syndrome / drug therapy*
  • Plasma Cells / drug effects
  • Plasma Cells / metabolism
  • Prednisone / administration & dosage
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / therapeutic use*
  • Pyrazines / therapeutic use*
  • Remission Induction
  • Vascular Endothelial Growth Factor A / blood
  • Vascular Endothelial Growth Factor A / metabolism
  • Vincristine / administration & dosage

Substances

  • Angiogenesis Inhibitors
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Cytarabine
  • Vincristine
  • Bortezomib
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Melphalan
  • Prednisone

Supplementary concepts

  • VAD regimen